<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Drug resistance</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Drug resistance rising: one in six infections show no response</title>
      <description>
        <![CDATA[One in six common bacterial infections diagnosed worldwide in 2023 were resistant to treatment with antibiotics, according to the latest surveillance data gathered by the World Health Organization (WHO). Drug-resistant gram-negative bacteria that cause bloodstream infections that can lead to sepsis, organ failure and death are an increasing threat globally.]]>
      </description>
      <guid>http://www.bioworld.com/articles/725002</guid>
      <pubDate>Mon, 13 Oct 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/725002-drug-resistance-rising-one-in-six-infections-show-no-response</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/bacteria-culture-drug-resistance-petri-dish-lab.webp?t=1741103935" type="image/jpeg" medium="image" fileSize="160105">
        <media:title type="plain">Art concept for antimicrobial research</media:title>
      </media:content>
    </item>
    <item>
      <title>TYRA-200: a potent oral FGFR inhibitor tackling resistance mutations</title>
      <description>
        <![CDATA[Tyra Biosciences Inc. recently presented the design and preclinical characterization of TYRA-200, an oral small-molecule FGFR1/2/3 tyrosine kinase inhibitor (TKI) that shows high potency against all common mutant forms of FGFR2 and holds potential for the treatment of cancers driven by FGFR2 alterations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723685</guid>
      <pubDate>Fri, 29 Aug 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723685-tyra-200-a-potent-oral-fgfr-inhibitor-tackling-resistance-mutations</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-mutation-variation.webp?t=1722524925" type="image/jpeg" medium="image" fileSize="179355">
        <media:title type="plain">Illustration of double helix </media:title>
      </media:content>
    </item>
    <item>
      <title>Kiwa antiviral defenses dissected to disarm bacteria</title>
      <description>
        <![CDATA[Bacteria also defend themselves against pathogen attacks using mechanisms like those of the immune system. But if there is a system to repel an attack, it can also be dismantled. Scientists at the University of Southampton have described the components of Kiwa, a protein complex that blocks the entry of phage DNA, which are viruses that infect bacteria. They have also uncovered how Kiwa interacts with other bacterial defense strategies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722717</guid>
      <pubDate>Thu, 31 Jul 2025 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722717-kiwa-antiviral-defenses-dissected-to-disarm-bacteria</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/7-31-University-of-Southampton-Collage-Kiwa.webp?t=1753973899" type="image/jpeg" medium="image" fileSize="644953">
        <media:title type="plain">Microscopic image of a bacteria infected by phage (left) and illustration of a phage attaching to a bacterial cell</media:title>
        <media:description type="plain">Left: Bacteria infected by phage; the dots show phages replicating. Right: This illustration shows a phage attaching to a bacterial cell. The Kiwa defense system (shown in yellow, green and blue) detects the threat and binds the invading DNA, preventing the phage from hijacking the cell. Credit: University of Southampton.</media:description>
      </media:content>
    </item>
    <item>
      <title>Boronic acid inhibitors restore cefepime efficacy in multidrug-resistant KPC-producing &lt;em&gt;K. pneumoniae&lt;/em&gt;</title>
      <description>
        <![CDATA[The boronic acid transition state inhibitors S-02030 and MB-076 were strategically designed to be active against cephalosporinases and carbapenemases, especially KPC (<em>Klebsiella pneumoniae</em> carbapenemase).]]>
      </description>
      <guid>http://www.bioworld.com/articles/717292</guid>
      <pubDate>Fri, 14 Feb 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717292-boronic-acid-inhibitors-restore-cefepime-efficacy-in-multidrug-resistant-kpc-producing-emk-pneumoniae-em</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Klebsiella-pneumoniae-colonies-petri-dish.webp?t=1739551421" type="image/jpeg" medium="image" fileSize="151083">
        <media:title type="plain">Klebsiella pneumoniae colonies in petri dish</media:title>
      </media:content>
    </item>
    <item>
      <title>APD-94, a dual functional inhibitor of Bmi-1 and tubulin</title>
      <description>
        <![CDATA[Researchers from Hebei Normal University and affiliated organizations presented the discovery and preclinical characterization of a novel B lymphoma Mo-MLV insertion region 1 (Bmi-1) expression inhibitor, APD-94, designed as an agent that could potentially overcome drug resistance in patients with colorectal cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717285</guid>
      <pubDate>Fri, 14 Feb 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717285-apd-94-a-dual-functional-inhibitor-of-bmi-1-and-tubulin</link>
    </item>
    <item>
      <title>Gates Foundation, Novo Nordisk Foundation and Wellcome set sights on antimicrobial resistance</title>
      <description>
        <![CDATA[The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.]]>
      </description>
      <guid>http://www.bioworld.com/articles/717241</guid>
      <pubDate>Thu, 13 Feb 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/717241-gates-foundation-novo-nordisk-foundation-and-wellcome-set-sights-on-antimicrobial-resistance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Bacterial-colonies-in-petri-dishes.webp?t=1646348605" type="image/png" medium="image" fileSize="426836">
        <media:title type="plain">Bacterial colonies in petri dishes</media:title>
      </media:content>
    </item>
    <item>
      <title>Combined strategy can prevent pancreatic cancer drug resistance</title>
      <description>
        <![CDATA[Understanding the mechanisms of resistance to cancer treatments is necessary to find effective therapies at different stages of the disease. Scientists at UT Southwestern Medical Center studied the most frequent mutation in pancreatic ductal adenocarcinoma (PDAC), identified an escape route to a therapy in clinical trials, blocked it with another experimental compound and reduced tumors in mice.]]>
      </description>
      <guid>http://www.bioworld.com/articles/716743</guid>
      <pubDate>Fri, 31 Jan 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/716743-combined-strategy-can-prevent-pancreatic-cancer-drug-resistance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/3D-illustration-of-pancreatic-cancer.webp?t=1738336763" type="image/jpeg" medium="image" fileSize="318760">
        <media:title type="plain">3D illustration of pancreatic cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>New carbapenemase identified in &lt;em&gt;C. freundii&lt;/em&gt; raises resistance concerns</title>
      <description>
        <![CDATA[In a recently published study, researchers based at Université Paris-Saclay identified OXA-1186, a novel carbapenemase related to the previously known OXA-198 enzyme, in a clinical isolate of <em>Citrobacter freundii</em>. This discovery underscores the ongoing challenge of antibiotic resistance in bacterial pathogens.]]>
      </description>
      <guid>http://www.bioworld.com/articles/715886</guid>
      <pubDate>Fri, 03 Jan 2025 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/715886-new-carbapenemase-identified-in-emc-freundii-em-raises-resistance-concerns</link>
    </item>
    <item>
      <title>Extrachromosomal DNA acts as joker for cancer cells </title>
      <description>
        <![CDATA[Cancer therapies can eliminate specific tumors based on their genetic content. However, some cancer cells survive. How do they do it? Part of the answer lies in extrachromosomal DNA (ecDNA), an ace up the tumors’ sleeve to adapt and evade attack. Three simultaneous studies in the journal <em>Nature</em> lay all the cards on the table, revealing ecDNAs’ content, their origin, their inheritance, their influence in cancer, and a way to combat them.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714456</guid>
      <pubDate>Wed, 13 Nov 2024 10:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714456-extrachromosomal-dna-acts-as-joker-for-cancer-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/stanford-ecdna-11-11.webp?t=1731345576" type="image/jpeg" medium="image" fileSize="122454">
        <media:title type="plain">Illustration of ecDNA inheritance in cancer</media:title>
        <media:description type="plain">ecDNAs that link together to enhance cancer cell growth tend to be inherited together by daughter cells after cell division (left). In contrast, ecDNAs that are inherited randomly give more genetic variability but may be less likely to spur tumor growth (right). Credit: Emily Moskal/Stanford Medicine</media:description>
      </media:content>
    </item>
    <item>
      <title>Extrachromosomal DNA acts as joker for cancer cells </title>
      <description>
        <![CDATA[Cancer therapies can eliminate specific tumors based on their genetic content. However, some cancer cells survive. How do they do it? Part of the answer lies in extrachromosomal DNA (ecDNA), an ace up the tumors’ sleeve to adapt and evade attack. Three simultaneous studies in the journal <em>Nature</em> lay all the cards on the table, revealing ecDNAs’ content, their origin, their inheritance, their influence in cancer, and a way to combat them.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714423</guid>
      <pubDate>Tue, 12 Nov 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714423-extrachromosomal-dna-acts-as-joker-for-cancer-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/stanford-ecdna-11-11.webp?t=1731345576" type="image/jpeg" medium="image" fileSize="122454">
        <media:title type="plain">Illustration of ecDNA inheritance in cancer</media:title>
        <media:description type="plain">ecDNAs that link together to enhance cancer cell growth tend to be inherited together by daughter cells after cell division (left). In contrast, ecDNAs that are inherited randomly give more genetic variability but may be less likely to spur tumor growth (right). Credit: Emily Moskal/Stanford Medicine</media:description>
      </media:content>
    </item>
    <item>
      <title>Extrachromosomal DNA acts as joker for cancer cells </title>
      <description>
        <![CDATA[Cancer therapies can eliminate specific tumors based on their genetic content. However, some cancer cells survive. How do they do it? Part of the answer lies in extrachromosomal DNA (ecDNA), an ace up the tumors’ sleeve to adapt and evade attack. Three simultaneous studies in the journal <em>Nature</em> lay all the cards on the table, revealing ecDNAs’ content, their origin, their inheritance, their influence in cancer, and a way to combat them.]]>
      </description>
      <guid>http://www.bioworld.com/articles/714318</guid>
      <pubDate>Mon, 11 Nov 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/714318-extrachromosomal-dna-acts-as-joker-for-cancer-cells</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/stanford-ecdna-11-11.webp?t=1731345576" type="image/jpeg" medium="image" fileSize="122454">
        <media:title type="plain">Illustration of ecDNA inheritance in cancer</media:title>
        <media:description type="plain">ecDNAs that link together to enhance cancer cell growth tend to be inherited together by daughter cells after cell division (left). In contrast, ecDNAs that are inherited randomly give more genetic variability but may be less likely to spur tumor growth (right). Credit: Emily Moskal/Stanford Medicine</media:description>
      </media:content>
    </item>
    <item>
      <title>Genome &amp; Co. stresses CNTN4-APP as next immuno-oncology target </title>
      <description>
        <![CDATA[Genome & Co. Ltd. has reported preclinical findings of its anti-CNTN4 antibody, GENA-104A16, and anti-APP antibody, 5A7 — stressing the contactin-4 (CNTN4) and amyloid precursor protein (APP) axis as a potential target for immuno-oncology. In the latest murine experiments, investigators led by Genome executives and researchers of Gwangju Institute of Science and Technology (GIST) found that blocking the interaction between CNTN4 and APP promoted cancer-destroying responses in mice, suggesting the pathway as a target for immunotherapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/713913</guid>
      <pubDate>Tue, 29 Oct 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/713913-genome-and-co-stresses-cntn4-app-as-next-immuno-oncology-target</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/cancer-tumor-crosshairs-target.webp?t=1711120097" type="image/jpeg" medium="image" fileSize="283816">
        <media:title type="plain">Concept art for targeting cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel quinolone-derivative tackles microbial resistance</title>
      <description>
        <![CDATA[The inappropriate use of antibiotics over long periods of time has led to increasing bacterial drug resistance. Quinolones are among the most effective and widely used antibacterials, and there are ongoing efforts to develop new quinolone-based drugs able to overcome emerging bacterial drug resistance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711836</guid>
      <pubDate>Mon, 26 Aug 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711836-novel-quinolone-derivative-tackles-microbial-resistance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Bacterial-colonies-in-petri-dishes.webp?t=1646348605" type="image/png" medium="image" fileSize="426836">
        <media:title type="plain">Bacterial colonies in petri dishes</media:title>
      </media:content>
    </item>
    <item>
      <title>Deazaflavin analog reverses MRP1-mediated drug resistance</title>
      <description>
        <![CDATA[Researchers from the University of Minnesota have presented the discovery and preclinical characterization of a novel potent inhibitor of multidrug resistance-associated protein 1 (MRP1), ZW-1226, that is being developed as a therapeutic candidate for the treatment of multidrug resistant (MDR) cancers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711170</guid>
      <pubDate>Fri, 02 Aug 2024 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711170-deazaflavin-analog-reverses-mrp1-mediated-drug-resistance</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration.webp?t=1711382891" type="image/jpeg" medium="image" fileSize="249152">
        <media:title type="plain">Drug discovery illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>NBS1 lactylation inhibition could avoid chemotherapy resistance</title>
      <description>
        <![CDATA[A study on the posttranslational modification through lactylation of non-histone proteins revealed a mechanism that participates in genome stability and provides resistance to chemotherapy. Scientists from The Second and The Seventh Affiliated Hospital of Sun Yat-sen University (SYSU) identified the lactation of the Nijmegen breakage syndrome 1 (NBS1) protein and the enzymes that participate in this process as a strategic point in cancer therapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/711094</guid>
      <pubDate>Thu, 01 Aug 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/711094-nbs1-lactylation-inhibition-could-avoid-chemotherapy-resistance</link>
    </item>
    <item>
      <title>Cancer cells adapt to resist therapy step by step</title>
      <description>
        <![CDATA[The adaptation of cancer cells to therapies limits the effectiveness of treatments. However, understanding the mechanisms they use to do it could help reverse them or be used to design more powerful drugs. Scientists at New York University (NYU) have studied the transitions causing resistance and have observed how it develops through a gradual process they have called the “resistance continuum.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/710715</guid>
      <pubDate>Tue, 23 Jul 2024 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/710715-cancer-cells-adapt-to-resist-therapy-step-by-step</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Ovarian-cancer-cell-variations-cluster.webp?t=1721747295" type="image/jpeg" medium="image" fileSize="353200">
        <media:title type="plain">Illustration of a cluster of ovarian cancer cells</media:title>
      </media:content>
    </item>
    <item>
      <title>Novel engineered lysin CF-370 is highly effective against resistant pathogens</title>
      <description>
        <![CDATA[Researchers from Contrafect Corp. have reported on the bactericidal activity of CF-370, a novel engineered lysin with broad-spectrum activity against gram-negative organisms, which are usually more resistant to antibacterial agents than gram-positive bacteria.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705746</guid>
      <pubDate>Mon, 26 Feb 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705746-novel-engineered-lysin-cf-370-is-highly-effective-against-resistant-pathogens</link>
    </item>
    <item>
      <title>Enzyme degrader could avoid drug resistance in B-cell cancers</title>
      <description>
        <![CDATA[Bruton tyrosine kinase (BTK) enzyme inhibitors used to treat B-cell cancers, including chronic lymphocytic leukemia and non-Hodgkin lymphoma, also produce resistance by causing mutations in the protein. Now, a study on the BTK degrader NX-2127 showed the compound could be effective in eliminating BTK regardless of its mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705640</guid>
      <pubDate>Fri, 09 Feb 2024 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705640-enzyme-degrader-could-avoid-drug-resistance-in-b-cell-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Non-Hodgkin-lymphoma-cells-in-the-blood-flow.webp?t=1642718747" type="image/png" medium="image" fileSize="492874">
        <media:title type="plain">Non-Hodgkin lymphoma cells in the blood flow</media:title>
      </media:content>
    </item>
    <item>
      <title>Enzyme degrader could avoid drug resistance in B-cell cancers</title>
      <description>
        <![CDATA[Bruton tyrosine kinase (BTK) enzyme inhibitors used to treat B-cell cancers, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, also produce resistance by causing mutations in the protein. Now, a study on the BTK degrader NX-2127 showed the compound could be effective in eliminating BTK regardless of its mutations.]]>
      </description>
      <guid>http://www.bioworld.com/articles/705482</guid>
      <pubDate>Thu, 08 Feb 2024 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/705482-enzyme-degrader-could-avoid-drug-resistance-in-b-cell-cancers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Non-Hodgkin-lymphoma-cells-in-the-blood-flow.webp?t=1642718747" type="image/png" medium="image" fileSize="492874">
        <media:title type="plain">Non-Hodgkin lymphoma cells in the blood flow</media:title>
      </media:content>
    </item>
    <item>
      <title>Old-fashioned screening approach yields new antibiotic class</title>
      <description>
        <![CDATA[Researchers have identified a new class of antibiotics that works by blocking the transportation of lipopolysaccharide (LPS) to the outer membrane of the gram-negative bacterium <em>Acinetobacter baumannii</em>. The most advanced member of the class, zosurabalpin (RG-6006, Roche AG), was effective against multiple <em>A.</em><em> baumannii</em> strains, including carbapenem-resistant and multidrug-resistant strains.]]>
      </description>
      <guid>http://www.bioworld.com/articles/704312</guid>
      <pubDate>Thu, 04 Jan 2024 09:00:55 -0500</pubDate>
      <link>https://www.bioworld.com/articles/704312-old-fashioned-screening-approach-yields-new-antibiotic-class</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Multidrug-resistant-A-baumannii.webp?t=1704384396" type="image/jpeg" medium="image" fileSize="208867">
        <media:title type="plain">Acinetobacter spp.</media:title>
        <media:description type="plain">A 3D computer-generated image of a group of multidrug-resistant Acinetobacter spp. bacteria. The artistic recreation was based upon scanning electron microscopic imagery. Credit: CDC/Antibiotic Resistance Coordination and Strategy Unit; James Archer, medical illustrator</media:description>
      </media:content>
    </item>
    <item>
      <title>Explainable AI finds new class of antibiotics</title>
      <description>
        <![CDATA[Researchers have used explainable artificial intelligence (explainable AI) to find structurally new antibiotics with minimal toxicity. They reported their findings online in <em>Nature</em> on Dec. 20, 2023. In animal testing, compounds identified via the method showed that they had activity against drug-resistant gram-positive bacteria including methicillin-resistant <em>Staphylococcus aureus</em> (MRSA), one of the most serious bacterial public health threats.]]>
      </description>
      <guid>http://www.bioworld.com/articles/703901</guid>
      <pubDate>Wed, 20 Dec 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/703901-explainable-ai-finds-new-class-of-antibiotics</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/MIT-Antibiotic-Predictions.webp?t=1703091717" type="image/jpeg" medium="image" fileSize="322721">
        <media:title type="plain">Bacteria targeted by technology concept art</media:title>
        <media:description type="plain">Using a type of artificial intelligence known as deep learning, MIT researchers have discovered a class of compounds that can kill a drug-resistant bacterium that causes more than 10,000 deaths in the U.S. every year. Credit: Christine Daniloff, MIT; Janice Haney Carr, CDC; iStock</media:description>
      </media:content>
    </item>
    <item>
      <title>Mission accomplished: Mission Bio launches MRD assay for blood cancer</title>
      <description>
        <![CDATA[Mission Bio Inc. released its Tapestri single-cell minimal residual disease (MRD) assay for acute myeloid leukemia (AML) on September 26, with the goal of enabling greater personalization of care for patients with blood cancers. The test can provide insights into the progression of AML and help identify targets for treatment in addition to identifying patients truly experiencing relapse as distinct from having pre-leukemic or precursor clones.]]>
      </description>
      <guid>http://www.bioworld.com/articles/701271</guid>
      <pubDate>Thu, 28 Sep 2023 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/701271-mission-accomplished-mission-bio-launches-mrd-assay-for-blood-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-acute-lymphoblastic-leukemia.webp?t=1676651893" type="image/png" medium="image" fileSize="1467255">
        <media:title type="plain">3D illustration of acute lymphoblastic leukemia in blood.</media:title>
      </media:content>
    </item>
    <item>
      <title>Cage fight could make for resistance-resistant antibiotic</title>
      <description>
        <![CDATA[A newly discovered antibiotic has been shown to block the synthesis of bacterial cell walls via immutable targets, raising the prospect of a class of drugs that will not lose effect through the development of antimicrobial resistance. Clovibactin, isolated from soil bacteria, targets the cell wall precursor molecules lipid II, lipid III and undecaprenyl phosphate (C55PP), all of which have a pyrophosphate group in common.]]>
      </description>
      <guid>http://www.bioworld.com/articles/700277</guid>
      <pubDate>Wed, 23 Aug 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/700277-cage-fight-could-make-for-resistance-resistant-antibiotic</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/Clovibactin-hero.webp?t=1692800559" type="image/jpeg" medium="image" fileSize="133656">
        <media:title type="plain">Clovibactin art concept</media:title>
        <media:description type="plain">Clovibactin uses an unsual cage-like binding motif to tightly wrap around pyrophosphate-containing lipids in bacterial cell membranes. Credit: Markus Weingarth, Utrecht University</media:description>
      </media:content>
    </item>
    <item>
      <title>Unraveling mechanisms of HIV-1 integrase resistance to DTG to design more effective drugs</title>
      <description>
        <![CDATA[Researchers from the U.S. National Institutes of Health and collaborators recently conducted a study investigating the mechanisms of HIV-1 resistance to integrase strand transfer inhibitors (INSTIs), such as the approved drug dolutegravir (DTG). They focused on understanding the mechanisms of resistance caused by mutations at positions 138, 140, and 148 and analyzed combinations of the mutations E138K, G140A/S, and Q148H/K/R, all conferring resistance to INSTIs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699902</guid>
      <pubDate>Fri, 11 Aug 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699902-unraveling-mechanisms-of-hiv-1-integrase-resistance-to-dtg-to-design-more-effective-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-HIV.webp?t=1724423365" type="image/jpeg" medium="image" fileSize="446919">
        <media:title type="plain">Transmission electron micrograph of HIV particles</media:title>
        <media:description type="plain">HIV-1 virus particles (colorized yellow) replicating from an HIV-infected H9 T cell (pink). Credit: NIAID, NIH</media:description>
      </media:content>
    </item>
    <item>
      <title>Improved LpxC inhibitor antibiotic ready for human trials</title>
      <description>
        <![CDATA[A different class of antibiotics could ease the increasing resistance triggered by some gram-negative bacteria. LpxC inhibitors are not new, but all attempts to develop them have failed due to cardiovascular toxicity or ineffectiveness. A modification of the structure of these compounds may have solved the problem. Duke University scientists demonstrated the preclinical safety and efficacy of an LpxC inhibitor candidate against a wide selection of these pathogens.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699821</guid>
      <pubDate>Thu, 10 Aug 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699821-improved-lpxc-inhibitor-antibiotic-ready-for-human-trials</link>
    </item>
    <item>
      <title>Communication system discovery explains how bacterial cells evolve</title>
      <description>
        <![CDATA[Bacteria cells are masters of adaptation and evolution, and by better understanding how they adapt and evolve, researchers hope to develop better drugs to fight microbial resistance, which is increasingly becoming a global public health threat. Researchers from the antimicrobial resistance interdisciplinary research group at the Singapore-MIT Alliance for Research and Technology (SMART) sought to understand the mechanisms bacteria use to adapt against stressors, and they discovered a new stress signaling system that sheds light on a new mechanism of antimicrobial resistance.]]>
      </description>
      <guid>http://www.bioworld.com/articles/699298</guid>
      <pubDate>Mon, 24 Jul 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/699298-communication-system-discovery-explains-how-bacterial-cells-evolve</link>
    </item>
    <item>
      <title>What stops a bad guy in the lung? A good guy in the lung, of course</title>
      <description>
        <![CDATA[Researchers at the Barcelona Institute of Science and Technology’s Center for Genomic Regulation (CRG) and Pulmobiotics Ltd. have used one bacterium to fight another. In mouse models, the team used engineered <em>Mycoplasma pneumoniae</em> to treat <em>Pseudomonas aeruginosa</em>, the chief culprit in ventilator-associated pneumonia (VAP).]]>
      </description>
      <guid>http://www.bioworld.com/articles/693484</guid>
      <pubDate>Fri, 20 Jan 2023 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/693484-what-stops-a-bad-guy-in-the-lung-a-good-guy-in-the-lung-of-course</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-source/CRG-Pseudomonas-aeruginosa.webp?t=1674229076" type="image/png" medium="image" fileSize="2120141">
        <media:title type="plain">Microscopic view of P. aeruginosa infection of mouse lung</media:title>
        <media:description type="plain">Cross-section of a mouse lung infected with P. aeruginosa and treated with engineered M. pneumoniae. Credit: Rocco Mazzolini/CRG</media:description>
      </media:content>
    </item>
    <item>
      <title>Researchers identify new class of antibiotic resistance mechanism</title>
      <description>
        <![CDATA[When a drug prevents bacteria from synthesizing their own folate, an essential compound for their survival, they take it directly from the host. This antibiotic resistance mechanism had not been detected until now because bacteria behave differently in the laboratory than they do in vivo during an infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/692296</guid>
      <pubDate>Thu, 08 Dec 2022 13:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/692296-researchers-identify-new-class-of-antibiotic-resistance-mechanism</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Antibiotic-resistant-bacteria.webp?t=1741101700" type="image/png" medium="image" fileSize="674752">
        <media:title type="plain">Antibiotic resistant bacteria inside a biofilm</media:title>
      </media:content>
    </item>
    <item>
      <title>Researchers identify new class of antibiotic resistance mechanism</title>
      <description>
        <![CDATA[When a drug prevents bacteria from synthesizing their own folate, an essential compound for their survival, they take it directly from the host. This antibiotic resistance mechanism had not been detected until now because bacteria behave differently in the laboratory than they do in vivo during an infection.]]>
      </description>
      <guid>http://www.bioworld.com/articles/692076</guid>
      <pubDate>Wed, 07 Dec 2022 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/692076-researchers-identify-new-class-of-antibiotic-resistance-mechanism</link>
    </item>
    <item>
      <title>Novel ocotillol derivative shows efficacy in preclinical models of P-gp-mediated MDR</title>
      <description>
        <![CDATA[P-glycoprotein (P-gp) is a multidrug resistance (MDR)-associated protein, which is widely distributed in membranes of several cells including hepatocytes, renal proximal tubular cells and brain capillary endothelial cells. The overexpression of this drug efflux transporter protein is considered to play a key role in the development of MDR.]]>
      </description>
      <guid>http://www.bioworld.com/articles/691007</guid>
      <pubDate>Thu, 27 Oct 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/691007-novel-ocotillol-derivative-shows-efficacy-in-preclinical-models-of-p-gp-mediated-mdr</link>
    </item>
  </channel>
</rss>
